TrueBinding (formally Immutics)

About TrueBinding (formally Immutics)

TrueBinding Inc. is a clinical-stage biotherapeutic company that develops novel monoclonal antibody therapeutics. These are lab-made proteins that can mimic the immune system's ability to fight off harmful pathogens such as bacteria and viruses. The company focuses on creating molecules for applications in various medical fields, including neurodegenerative and metabolic diseases, stroke, oncology, and other areas with significant unmet medical needs.

TrueBinding's primary market is the biopharmaceutical industry, where it offers contract development and manufacturing services. By using advanced technology and expertise, TrueBinding can speed up the development process, ensuring rapid and efficient production of high-quality monoclonal antibodies. This allows their clients to bring innovative therapies to market faster and more cost-effectively.

One of TrueBinding's key projects is the TB006 Expanded Access Program, which provides access to investigational medications for patients who have exhausted all other alternatives for combating Alzheimer’s Disease. The company has recently completed a Phase 1b/2a Clinical Trial for Alzheimer's Disease, with data showing potential improvements in patients' cognition and function.

TrueBinding generates revenue through its contract development and manufacturing services. By offering these services to other biopharmaceutical companies, TrueBinding can monetize its expertise and technology. Additionally, the company may also generate income from the commercialization of its proprietary therapeutics upon successful completion of clinical trials and regulatory approval.